Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.33 CAD | +7.87% | +10.43% | -13.70% |
04-17 | NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update | MT |
04-17 | NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 163M 223M 12.99B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.07% |
1 day | +7.87% | ||
1 week | +10.43% | ||
Current month | +10.95% | ||
1 month | -0.43% | ||
3 months | -33.24% | ||
6 months | +29.44% | ||
Current year | -13.70% |
Managers | Title | Age | Since |
---|---|---|---|
William Radvak
FOU | Founder | 61 | 18/01/17 |
Michael Kelly
CEO | Chief Executive Officer | 59 | 09/04/23 |
Bill Adams
DFI | Director of Finance/CFO | 62 | 23/02/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Randall Kaye
BRD | Director/Board Member | 62 | 27/10/20 |
Brian Bayley
BRD | Director/Board Member | 71 | 15/05/18 |
William Radvak
FOU | Founder | 61 | 18/01/17 |
Date | Price | Change | Volume |
---|---|---|---|
03/05/24 | 2.33 | +7.87% | 261,878 |
02/05/24 | 2.16 | +5.37% | 188,939 |
01/05/24 | 2.05 | -2.38% | 58,205 |
30/04/24 | 2.1 | +1.94% | 140,868 |
29/04/24 | 2.06 | -2.37% | 56,626 |
Delayed Quote Toronto S.E., May 03, 2024 at 08:59 pm
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.70% | 119M | |
+25.69% | 47.86B | |
+46.90% | 41.42B | |
-3.46% | 40.66B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+28.07% | 12.14B | |
+0.17% | 12.15B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- NGEN Stock